A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Primary objectives • To assess the time from randomisation until an improvement within 84 days defined as two points on a seven point ordinal scale or live discharge from the hospital in high-risk patients (group 1 to group 4) with SARS-CoV-2 infection requiring hospital admissio...

Full description

Bibliographic Details
Main Authors: Maike Janssen, Ulrike Schäkel, Carine Djuka Fokou, Johannes Krisam, Jacek Stermann, Katharina Kriegsmann, Isabella Haberbosch, Jan Philipp Novotny, Stefan Weber, Maria Vehreschild, Martin Bornhäuser, Lars Bullinger, Michael Schmitt, Tobias Liebregts, Peter Dreger, Hanns-Martin Lorenz, Anna Plaszczyca, Ralf Bartenschlager, Barbara Müller, Hans-Georg Kräusslich, Niels Halama, Dirk Jäger, Richard F. Schlenk, Albrecht Leo, Stefan Meuer, Markus A. Weigand, Johann Motsch, Uta Merle, Claudia M. Denkinger, Carsten Müller-Tidow
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
protocol
convalescent plasma
early application
high-risk patients with severe disease
Online Access:http://link.springer.com/article/10.1186/s13063-020-04735-y

Internet

http://link.springer.com/article/10.1186/s13063-020-04735-y

Similar Items